Logo

MLEC

Moolec Science S.A.

MLEC

Moolec Science S.A. • NASDAQ
$0.40 ▼ -2.34% (-0.01)
Market Cap $4.36 M
52w High $10.47
52w Low $0.39
Dividend Yield 0%
P/E -0.19
Volume 29.54K
Outstanding Shares 10.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2024 $2.643M ▲ $1.385M ▼ $-2.427M ▼ -91.84% ▲ $-0.06 ▼ $-1.152M ▼
Q1-2024 $1.557M ▲ $2.116M ▼ $-1.915M ▲ -123.025% ▲ $-0.05 ▲ $-1.069M ▲
Q4-2023 $1.523M ▼ $2.868M ▲ $-2.536M ▼ -166.47% ▼ $-0.07 ▼ $-2.365M ▼
Q3-2023 $2.11M ▲ $2.134M ▲ $-1.402M ▲ -66.461% ▲ $-0.04 ▲ $-627.062K ▲
Q2-2023 $252.114K $1.974M $-1.784M -707.425% $-0.05 $-1.732M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2024 $1.93M ▼ $31.381M ▼ $28.585M ▲ $2.797M ▼
Q1-2024 $3.61M ▼ $32.558M ▼ $26.865M ▼ $5.693M ▼
Q4-2023 $5.39M ▲ $34.787M ▲ $27.971M ▲ $6.816M ▲
Q3-2023 $4.252M ▲ $25.952M ▲ $19.313M ▲ $6.639M ▼
Q2-2023 $1.834M $21.321M $14.637M $6.684M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2024 $-2.427M ▼ $-890.483K ▲ $-298.861K ▼ $-529.902K ▲ $-1.68M ▲ $-1.189M ▼
Q1-2024 $-1.915M ▲ $-1.126M ▼ $-59.738K ▼ $-542.417K ▼ $-1.78M ▼ $-1.186M ▼
Q4-2023 $-2.535M ▼ $-1.04M ▲ $-24.048K ▼ $2.202M ▼ $1.138M ▼ $-1.071M ▲
Q3-2023 $-1.402M ▲ $-2.64M ▲ $112.476K ▲ $4.817M ▼ $2.55M ▲ $-2.67M ▲
Q2-2023 $-1.784M $-4.058M $-128.125K $4.974M $847.889K $-4.05M

Five-Year Company Overview

Income Statement

Income Statement Moolec is essentially still a pre‑revenue company: it has only just started to record a token amount of sales, and its core business is not yet commercial. The income statement is dominated by operating losses tied to research, development, and overhead rather than to production or scale. Losses have been meaningful relative to the company’s small size, and per‑share results have been volatile, partly influenced by its SPAC origins and subsequent capital structure changes. Overall, the profile is that of an early‑stage biotech/food‑tech firm investing ahead of revenue, rather than a mature operating business.

Balance Sheet

Balance Sheet The balance sheet is small and reflects a company still in the build‑out phase. Assets and equity are limited, with only a modest cash cushion and a relatively new layer of financial debt, which slightly increases financial risk. There is not yet a strong asset base from productive facilities or large intangible balances; instead, value is mostly in technology, know‑how, and partnerships that do not fully appear in the numbers. The balance sheet looks fragile and likely dependent on continued access to external funding over time.

Cash Flow

Cash Flow Moolec is consistently consuming cash rather than generating it. Operating cash flows are negative, reflecting spending on staff, R&D, and company infrastructure without offsetting sales. Free cash flow is also negative, although capital spending so far appears light, meaning most of the cash burn is from operating activities, not heavy equipment investment. The business model and stage imply that additional funding rounds, cost discipline, or partnerships will be important to sustain development until meaningful revenue arrives.

Competitive Edge

Competitive Edge Competitively, Moolec is trying to carve out a differentiated niche in “molecular farming,” using crops as factories for animal proteins and specialty ingredients. Its advantages include early scientific leadership, a focused platform, and a growing patent portfolio that can act as a barrier to direct imitation. The planned business combination with Bioceres could significantly strengthen its position by adding seed technology, distribution, and agricultural relationships, turning Moolec from a pure technology story into part of a broader ag‑tech ecosystem. At the same time, the company faces intense indirect competition from other alternative protein and ingredients technologies, plus regulatory, scaling, and adoption hurdles that larger food and ag players might be better resourced to navigate.

Innovation and R&D

Innovation and R&D Innovation is the core of Moolec’s story. The company’s molecular farming platform, highlighted by products like Piggy Sooy™ (pork‑protein soybeans) and GLASO™ (a high‑GLA safflower oil), aims to produce high‑value animal proteins and oils directly in plants at farm scale. A meaningful patent portfolio and regulatory progress for Piggy Sooy™ suggest real technical depth, while GLASO™ already has an offtake agreement, indicating commercial interest. The pipeline appears broader than just these two products, and the Bioceres combination should expand R&D resources and application areas, but success still depends on proving consistent yields, regulatory approvals, cost advantages, and consumer and customer acceptance of genetically engineered ingredients.

Summary

Moolec today is best understood as a high‑concept, early‑stage platform company rather than a traditional operating business. Financially, it is pre‑revenue, loss‑making, and cash‑consuming, with a modest and somewhat delicate balance sheet, implying ongoing reliance on external capital or strategic partners. Strategically, it sits at the intersection of biotech, agriculture, and alternative proteins, with a distinctive technology approach, notable IP, and a potentially transformative merger with Bioceres that could give it scale and commercial reach. The main opportunities lie in successful commercialization of Piggy Sooy™ and GLASO™, expansion of the product pipeline, and realization of merger synergies, while the main risks center on funding needs, regulatory outcomes, technical execution at scale, and market acceptance of its novel ingredients.

NEWS

November 28, 2025 · 1:15 PM UTC

Moolec Receives Nasdaq Determination Letter

Read more

September 11, 2025 · 7:00 AM UTC

Moolec Science Secures Regulatory Approval for Safflower GLASO Technology in Argentina, Expands U.S. Acreage, and Strengthens Leadership With CFO Appointment

Read more